TY - JOUR
T1 - Healthcare expenditure and its predictors in a cohort of Australians living with sciatica
AU - Chye, Alexander
AU - Lin, Chung Wei Christine
AU - Hancock, Mark J.
AU - Harris, Ian
AU - Latimer, Jane
AU - Maher, Christopher G.
AU - McLachlan, Andrew J.
AU - Mathieson, Stephanie
AU - Koes, Bart
AU - Day, Richard O.
AU - Billot, Laurent
AU - Jan, Stephen
AU - Angell, Blake
N1 - Funding Information:
AC, CL, SJ, JL, BK, RD, LB and BA declare no conflict of interest. CM received support from PHP International Pty Ltd for supply of heat wraps to a clinical trial; AM received support from GlaxoSmithKline Australia for a Ph.D. scholarship under his supervision. The authors confirm full control of all primary data and are happy for the journal to review if requested.
Funding Information:
This research was completed without funding. The original trial Pregabalin in Addition to Usual Care for Sciatica (PRECISE) was supported by a Grant (ID APP1042073) from the National Health and Medical Research Council of Australia with in-kind support from Pfizer Australia. Investigators of the PRECISE trial retained full autonomy over the design, conduct, analysis and reporting of the trial.
Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2021/4
Y1 - 2021/4
N2 - Purpose: To estimate the healthcare resource utilisation of an Australian cohort of people with sciatica and explore individual-level factors associated with expenditure. Methods: Healthcare utilisation (services and medication) data from a randomised, double-blind, placebo-controlled trial of pregabalin in patients with sciatica (n = 185) were analysed to estimate healthcare expenditure of participants over 12 months. Associations between key baseline socio-economic, pain and quality of life characteristics and healthcare expenditure were examined using generalised linear imputation models. Results: On average, participants accessed AUD$1,134 of healthcare over the year, predominantly made up of $114 of medication and $914 of health services, which included $418 of physiotherapy services. Participants randomised to receive pregabalin incurred higher expenditure ($1,263 compared to $1,001 for placebo), which was largely driven by pregabalin ($158) and greater health services ($107). Healthcare expenditure was significantly higher for participants prescribed pregabalin, earning greater than $1,700 per week ($88,400 per year) and reporting poorer quality of life (physical and mental). Conclusion: Our results suggest inefficiency in the use of healthcare resources due to increased healthcare resource utilisation in people with sciatica treated with pregabalin, compared to placebo. Costs of treating sciatica varied based on individual quality of life and socio-economic characteristics.
AB - Purpose: To estimate the healthcare resource utilisation of an Australian cohort of people with sciatica and explore individual-level factors associated with expenditure. Methods: Healthcare utilisation (services and medication) data from a randomised, double-blind, placebo-controlled trial of pregabalin in patients with sciatica (n = 185) were analysed to estimate healthcare expenditure of participants over 12 months. Associations between key baseline socio-economic, pain and quality of life characteristics and healthcare expenditure were examined using generalised linear imputation models. Results: On average, participants accessed AUD$1,134 of healthcare over the year, predominantly made up of $114 of medication and $914 of health services, which included $418 of physiotherapy services. Participants randomised to receive pregabalin incurred higher expenditure ($1,263 compared to $1,001 for placebo), which was largely driven by pregabalin ($158) and greater health services ($107). Healthcare expenditure was significantly higher for participants prescribed pregabalin, earning greater than $1,700 per week ($88,400 per year) and reporting poorer quality of life (physical and mental). Conclusion: Our results suggest inefficiency in the use of healthcare resources due to increased healthcare resource utilisation in people with sciatica treated with pregabalin, compared to placebo. Costs of treating sciatica varied based on individual quality of life and socio-economic characteristics.
UR - http://www.scopus.com/inward/record.url?scp=85091428591&partnerID=8YFLogxK
U2 - 10.1007/s00586-020-06605-2
DO - 10.1007/s00586-020-06605-2
M3 - Article
C2 - 32970236
AN - SCOPUS:85091428591
VL - 30
SP - 878
EP - 885
JO - European Spine Journal
JF - European Spine Journal
SN - 0940-6719
IS - 4
ER -